Alzheimer’s disease (AD) is the most common progressive neurodegenerative disorder associated with aging. Limited success of recent clinical trials of various AD treatments may be attributable to treating the disease too late. AivoCode is developing specific probes that recognize AD signature present in the brain. These probes can be used for therapeutic delivery and non-invasive detection of early AD.

Traumatic brain injury (TBI) impacts over 2.5 million people annually in the US. AivoCode has licensed technology from Sanford Burnham Prebys Medical Discovery Institute (SBP) to improve delivery of therapeutic or an imaging payload from systemic circulation to the injured part of the brain.

Age-related macular degeneration (AMD)

AMD is the most common cause of severe loss of eyesight among people 50 years of age and older. The therapeutic market for neovascular AMD is over $10 billion. More than half of wet AMD patients on anti-VEGF treatments continue to experience vision loss over time due to the development of subretinal fibrosis. There are currently no effective therapies to prevent or treat fibrosis. AivoCode is developing a first-in-class intravitreal therapeutic to inhibit subretinal fibrosis, a known and unaddressed complication in patients with wet AMD.